Oncology pharmacist here,
After reviewing primary literature, it seems that I cannot make a decision either way.
The data is conflicting regarding the use of mesalamine for prevention of CRC in the IBD population. It appears that many studies contradict each other. In addition, physicians at my hospitals have opposing views on the matter.
In mild cases such as proctitis, some choose to continue maintenence oral mesalamine in patients that have experienced remission on suppositories alone with no subsequent episodes while some d/c the drug at remission and watch and wait. Some decide to use both topical and oral therapy at diagnosis indefinitely. While others pick one route and stick with that.
Hoping to get some input from others in different facilities and schools of thought.
Thanks!
After reviewing primary literature, it seems that I cannot make a decision either way.
The data is conflicting regarding the use of mesalamine for prevention of CRC in the IBD population. It appears that many studies contradict each other. In addition, physicians at my hospitals have opposing views on the matter.
In mild cases such as proctitis, some choose to continue maintenence oral mesalamine in patients that have experienced remission on suppositories alone with no subsequent episodes while some d/c the drug at remission and watch and wait. Some decide to use both topical and oral therapy at diagnosis indefinitely. While others pick one route and stick with that.
Hoping to get some input from others in different facilities and schools of thought.
Thanks!
Last edited:
I am sure you are the belle of the ball as well.
